Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from pharmacy benefit managers. Such insurers are often building obstacles to coverage, such as steep cost requirements and approval processes that hinder user access.… Read More